Discussion Treatment with antipsychotic drugs such as olanzapine can result in severe metabolic consequences such as hyperglycemia, dysregulated lipid metabolism, weight gain and the development of type 2 diabetes, in a population that suffers from premature cardiovascular mortality ( GLP1 receptor agonists such as liraglutide have proven to be effective pharmacological tools to reduce weight gain in individuals treated with antipsychotics [( A potential confounder to the current experiments is that we cannot account for other hormones that might be stimulated by oral glucose and preserved by inhibition of DPPiv such as gastric inhibitory peptide (GIP), an incretin hormone and substrate of DPPiv ( Treatment with GLP1 receptor agonists are effective and generally well-tolerated but they can be limited by the requirement of repeated injections, dose escalation, nausea, and injection-site reactions ( Findings from the current investigation provide proof of principle that increasing endogenous levels of GLP1 can provide therapeutic benefit in alleviating the metabolic side effects of olanzapine

Results showed that the experimental protocol led to significantly lower respiratory quotient values at 4, 5, 7, 11, and 12 min, suggesting enhanced fat oxidation
Its essential to be aware of potential side effects, risks, and what may happen if you stop taking them
In a licensed clinical trial, participants and site staff will receive precise, validated storage instructions from the trial sponsor, in accordance with the MHRA Good Clinical Practice (GCP) Guide and EU/UK Good Distribution Practice (GDP) guidelines